Tumor lysis syndrome after treatment of a gastrointestinal stromal tumor with the oral tyrosine kinase inhibitor sunitinib.
Saylor
Philip J
PJ
Department of Oncology, University of California, San Diego, CA, USA.
Reid
Tony R
TR
D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000009:adverse effects*; D017809:Fatal Outcome; D005770:Gastrointestinal Neoplasms / Q000150:complications* / Q000188:drug therapy* / Q000401:mortality; D046152:Gastrointestinal Stromal Tumors / Q000150:complications* / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011758:Pyrroles / Q000009:adverse effects*; D000077210:Sunitinib; D015275:Tumor Lysis Syndrome / Q000175:diagnosis* / Q000209:etiology* / Q000401:mortality
D000970:Antineoplastic Agents; D007211:Indoles; D047428:Protein Kinase Inhibitors; D011758:Pyrroles; D000077210:Sunitinib